延边地区2020年丙型肝炎抗体筛查结果分析

周旸; 付朝旭; 周敏; 徐蕾; 李明阳; 沈瀛生; 朴红心; 杨恩月

doi:10.3969/j.issn.1001-5256.2022.07.011

延边地区2020年丙型肝炎抗体筛查结果分析

DOI: 10.3969/j.issn.1001-5256.2022.07.011

周旸¹,
付朝旭¹,
周敏¹,
徐蕾¹,
李明阳²,
沈瀛生²,
朴红心^1, , ,,
杨恩月^1, , ,

1.
延边大学附属医院感染性疾病科，吉林延吉 133002
2.
中联肝健康促进中心，北京 100071

基金项目:

中联肝健康促进中心-消除丙肝公益项目 (20170903);

国家自然科学基金 (81360075);

吉林省卫生健康科技能力提升项目 (2021LC077)

伦理学声明：本次筛查活动于2018年12月3日通过延边大学附属医院医学伦理委员会审查，批号为延医伦理2018143号。

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：周旸、周敏负责课题设计，收集数据，资料分析，撰写论文；付朝旭、徐蕾、李明阳、沈瀛生参与修改论文；朴红心、杨恩月负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
朴红心，15526770394@163.com

杨恩月，enyueyang@163.com

计量
- 文章访问数: 533
- HTML全文浏览量: 227
- PDF下载量: 48
- 被引次数: 0
出版历程
- 收稿日期: 2021-12-02
- 录用日期: 2022-01-29
- 出版日期: 2022-07-20

Analysis of the results of hepatitis C antibody screening in 2020 in Yanbian area of China

Yang ZHOU¹,
Chaoxu FU¹,
Min ZHOU¹,
Lei XU¹,
Mingyang LI²,
Yingsheng SHEN²,
Hongxin PIAO^{1
, ,
,},
Enyue YANG^{1
, ,
,}

1.
Department of Infectious Diseases, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133002, China
2.
China Liver Health, Beijing 100071, China

Research funding:

Zhonglian Liver Health Promotion Center- Public Welfare Project for the Elimination of Hepatitis C (20170903);

National Natural Science Foundation of China (81360075);

Jilin Provincial Health Science and Technology Capacity Enhancement Project (2021LC077)

More Information

Corresponding author: PIAO Hongxin, 15526770394@163.com(ORCID: 0000-0002-3294-9937); YANG Enyue, enyueyang@163.com(ORCID: 0000-0002-2323-4526)

摘要

摘要: 目的研究影响丙型肝炎抗体的相关因素及评价近7年来延边州对于丙型肝炎的预防效果。方法 2020年随机筛选1184例延边地区居民，采取指尖血标本，使用胶体金法试剂检测丙型肝炎抗体，将2020年丙型肝炎抗体阳性率与2013年的数据进行对比分析。计数资料组间比较采用χ²检验或Fisher精确检验，Fisher精确检验后使用成对比较分析。结果 2020年筛选的延边州居民丙型肝炎抗体阳性率(6.42%)低于2013年(10.60%)(χ²=11.212，P=0.001)；2020年各个年龄段之间丙型肝炎抗体阳性率经Fisher精确检验(2×C)结果显示，5个年龄段之间差异具有统计学意义(χ²=29.478，P＜0.001)；采用Bonferroni调整后成对比较显示≥60岁组与50~59岁组、40~49岁组、30~39岁之间差异具有统计学意义(χ²值分别为11.268、14.804、9.293，P值均＜0.01)，其余各组间差异无统计学意义(P＞0.01)。朝鲜族抗体阳性率(10.45%)显著高于非朝鲜族抗体阳性率(5.50%)(χ²=7.236，P=0.007)；在农民群体中，2020年丙型肝炎抗体阳性率(7.16%)低于2013年(19.74%)(χ²=36.604，P＜0.001)；农村地区(7.33%)丙型肝炎抗体阳性率高于城市(4.26%)(χ²=3.882，P=0.049)。结论丙型肝炎抗体阳性率主要与年龄、民族、职业、地域有关。7年来延边地区丙型肝炎抗体阳性率较前下降，延边州对于丙型肝炎的初步防治效果较为显著。
- 丙型肝炎抗体 /
- 延边地区 /
- 多相筛查
Abstract: Objective To investigate the influencing factors for hepatitis C antibody and the preventive effect of hepatitis C in Yanbian Prefecture of China in the recent 7 years. Methods A total of 1184 residents in Yanbian were randomly selected in 2020, peripheral blood samples were collected, and the colloidal gold method was used to detect hepatitis C antibody. The positive rate of hepatitis C antibody in 2020 was compared with the data in 2013. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups, and then pairwise comparison was performed. Results The positive rate of hepatitis C antibody in Yanbian residents screened in 2020 was significantly lower than that in 2013 (6.42% vs 10.60%, χ²=11.212, P=0.001). The Fisher's exact test (2×C) was performed for the positive rate of hepatitis C antibody between different age groups in 2020, and the results showed that there was a significant difference between the 5 age groups (χ²=29.478, P < 0.001). Pairwise comparison after Bonferroni adjustment showed that there was a significant difference between the≥60 years group and the 50-59 years group, between the≥60 years group and the 40-49 years group, and between the≥60 years group and the 30-39 years group (χ²=11.268, 14.804, and 9.293, all P < 0.01), while there was no significant difference between the other groups (P > 0.01). The Chinese Korean population had a significantly higher positive rate of antibody than the non-Chinese Korean population (10.45% vs 5.50%, χ²=7.236, P=0.007). As for the farmers, the positive rate of hepatitis C antibody in 2020 was significantly lower than that in 2013 (7.16% vs 19.74%, χ²=36.604, P < 0.001). The positive rate of hepatitis C antibody in rural areas was significantly higher than that in urban areas (7.33% vs 4.26%, χ²=3.882, P=0.049). Conclusion The positive rate of hepatitis C antibody is mainly associated with age, nationality, occupation, and region. There is a reduction in the positive rate of hepatitis C antibody in Yanbian in the recent 7 years, suggesting that Yanbian Prefecture has achieved a marked effect in the prevention and treatment of hepatitis C.
- Hepatitis C Antibodies /
- Yanbian Area /
- Multiphasic Screening

HTML全文

表 1 2013年与2020年不同年龄阶段丙型肝炎抗体阳性率比较

Table 1. Comparison of positive rate of hepatitis C antibody in different age groups in 2013 and 2020

年龄段	丙型肝炎抗体阳性率		χ²值	P值
年龄段	2013年	2020年	χ²值	P值
＜30岁	0(0/108)	0(0/31)
30~39岁	2.70%(4/148)	0(0/71)		0.307
40~49岁	6.70%(15/224)	2.97%(7/236)	3.512	0.061
50~59岁	18.18%(32/176)	5.37%(24/447)	25.341	＜0.001
≥60岁	23.29%(34/146)	11.78%(47/399)	11.188	0.001

下载: 导出CSV

参考文献(23)

[1]	PIETSCHMANN T, BROWN R. Hepatitis C virus[J]. Trends Microbiol, 2019, 27(4): 379-380. DOI: 10.1016/j.tim.2019.01.001.
[2]	THOMAS DL. Global control of hepatitis C: where challenge meets opportunity[J]. Nat Med, 2013, 19(7): 850-858. DOI: 10.1038/nm.3184.
[3]	Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 161-176. DOI: 10.1016/S2468-1253(16)30181-9.
[4]	SUN HQ, XIAO GX, GUO Y, et al. Spatial clustering and changing trend of hepatitis C prevalence during 2008-2012 in China[J]. China Public Health, 2014, 30(3): 286-289. DOI: 10.11847/zgggws2014-30-03-10. 孙海泉, 肖革新, 郭莹, 等. 中国2008—2012年丙肝流行规律及空间聚集性分析[J]. 中国公共卫生, 2014, 30(3): 286-289. DOI: 10.11847/zgggws2014-30-03-10.
[5]	LU XR, ZHAO QL. Epidemiological characteristics of viral hepatitis C in Jilin Province, 2008-2017[J]. Pract Prevent Med, 2019, 26(7): 805-807. DOI: 10.3969/j.issn.1006-3110.2019.07.009. 卢欣荣, 赵庆龙. 2008-2017年吉林省丙型病毒性肝炎流行病学特征[J]. 实用预防医学, 2019, 26(7): 805-807. DOI: 10.3969/j.issn.1006-3110.2019.07.009.
[6]	Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[7]	Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008. 中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 临床肝胆病杂志, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
[8]	YANG J, RAO HY. EASL recommendations on treatment of hepatitis C: Final update of the series (2020)[J]. J Clin Hepatol, 2020, 36(12): 2681-2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009. 杨甲, 饶慧瑛. 2020年欧洲肝病学会推荐意见: 丙型肝炎的治疗(最终更新版)[J]. 临床肝胆病杂志, 2020, 36(12): 2681-2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009.
[9]	WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(2): 127-134. DOI: 10.1016/S2468-1253(18)30343-1.
[10]	ZHOU Q, YANG LH, JIANG FQ. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. J Clin Hepatol, 2021, 37(8): 1836-1840. DOI: 10.3969/j.issn.1001-5256.2021.08.018. 周荃, 杨丽晖, 蒋芳清. 直接抗病毒药物改善HCV相关肝细胞癌患者远期预后效果的Meta分析[J]. 临床肝胆病杂志, 2021, 37(8): 1836-1840. DOI: 10.3969/j.issn.1001-5256.2021.08.018.
[11]	GAO Y, YANG J, SUN F, et al. Prevalence of anti-HCV antibody among the general population in mainland China between 1991 and 2015: A systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(3): ofz040. DOI: 10.1093/ofid/ofz040.
[12]	CALVARUSO V, PETTA S, CRAXÌ A. Is global elimination of HCV realistic?[J]. Liver Int, 2018, 38(Suppl 1): 40-46. DOI: 10.1111/liv.13668.
[13]	DORE GJ, BAJIS S. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(2): 91-92. DOI: 10.1038/s41575-020-00392-3.
[14]	CHEN LN, JIN LZ, SUN LB, et al. Survey and analysis of HCV antibody positivity among 802 community-dwelling adults in Yanbian Prefecture, Jilin Province, China[J]. Chronic Pathematol J, 2013, 14(6): 463-464. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201306023.htm 陈龙男, 金龙洙, 孙鲁白, 等. 吉林省延边州802名社区居民HCV抗体阳性率调查分析[J]. 慢性病学杂志, 2013, 14(6): 463-464. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201306023.htm
[15]	LITAKER JR, TAMEZ N, LOPEZ BRAY C, et al. Hepatitis C antibody screening among baby boomers by a community-based health insurance company[J]. Popul Health Manag, 2021, 24(4): 492-495. DOI: 10.1089/pop.2020.0214.
[16]	MOORMAN AC, DROBENUIC J, KAMILI S. Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007-2012[J]. J Clin Virol, 2017, 89: 1-4. DOI: 10.1016/j.jcv.2017.01.007.
[17]	CUI FQ, ZHUANG H. Progress in prevention and control of viral hepatitis since the establishing of the People's Republic of China[J]. Chin J Hepatol, 2021, 29(8): 725-731. DOI: 10.3760/cma.j.cn501113-20210722-00351. 崔富强, 庄辉. 中国建国以来防控病毒性肝炎工作进展[J]. 中华肝脏病杂志, 2021, 29(8): 725-731. DOI: 10.3760/cma.j.cn501113-20210722-00351.
[18]	TRICKEY A, SOOD A, MIDHA V, et al. Clustering of hepatitis C virus antibody positivity within households and communities in Punjab, India[J]. Epidemiol Infect, 2019, 147: e283. DOI: 10.1017/S0950268819001705.
[19]	XU HM, KONG YM. Mother-infant relationship in chronic hepatitis B and chronic hepatitis C[J]. Chin J Pract Pediatr, 2010, 25(12): 912-915. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201012010.htm 许红梅, 孔元梅. 慢性乙型肝炎和慢性丙型肝炎的母婴传播[J]. 中国实用儿科杂志, 2010, 25(12): 912-915. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201012010.htm
[20]	GAO YH, LIU XE, ZHUANG H. Research progress on hepatitis C in children[J]. Chin J Viral Dis, 2016, 6(4): 300-306. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201604015.htm 高玉华, 刘学恩, 庄辉. 儿童丙型肝炎研究进展[J]. 中国病毒病杂志, 2016, 6(4): 300-306. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201604015.htm
[21]	MIAO N, JIN LZ, PIAO HX, et al. Study on risk factors of hepatitis C virus infection in Yanbian Korean Prefecture Chinese[J]. Chin J Vaccines Immun, 2013, 19(2): 159-163. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201302019.htm 缪宁, 金龙洙, 朴红心, 等. 延边朝鲜族自治州丙型肝炎病毒感染危险因素研究[J]. 中国疫苗和免疫, 2013, 19(2): 159-163. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201302019.htm
[22]	PIAO HJ, ZHANG YZ, CHEN N, et al. Comparative study of risk factors for HCV infection between Korean-Chinese and Han nationality in Yanbian area[J]. J Med Sci Yanbian Univ, 2015, 38(4): 333-336. DOI: 10.16068/j.1000-1824.2015.04.035. 朴海今, 张英哲, 陈宁, 等. 延边地区朝鲜族与汉族丙型肝炎病毒感染危险因素比较研究[J]. 延边大学医学学报, 2015, 38(4): 333-336. DOI: 10.16068/j.1000-1824.2015.04.035.
[23]	PIAO HX, YANG AT, SUN YM, et al. Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China[J]. PLoS One, 2014, 9(1): e86190. DOI: 10.1371/journal.pone.0086190.